As part of an ongoing global study, MemorialCare Long Beach Center has administered the antiviral drug Remdesivir to three patients as a possible treatment for COVID-19. This news comes closely after Gilead, a biotech company based out of the California Bay Area, published their compassionate use data and found that out of 53 patients that exhibited severe respiratory symptoms were treated with Remdesivir; of those patients, 68% have experienced clinical improvement. While this data is too small to be considered statistically significant, Kevin Jones, MD, Medical Director of MemorialCare Office of Research Administration remains hopeful “that this drug will have a positive impact on these patients.” 

For more information, see here

More on: